Verve Therapeutics Inc
Abrir
0
Visão Geral
Variação de preço das ações
24h
Mín
Máximo
Recomendações | Comprar |
|---|---|
Previsão para 12 meses | +29.02% upside |
Pontuação Técnica
By Trading Central
Confiança
Strong Bearish Evidence
Verve Therapeutics Inc Gráfico
O desempenho passado não é um indicador confiável de resultados futuros.
Notícias Relacionadas
Comparação entre Pares
Variação de preço
Verve Therapeutics Inc Previsão
Preço-alvo
By TipRanks
29.02% parte superior
Previsão para 12 meses
Média 14.36 USD 29.02%
Máximo 24 USD
Mínimo 11 USD
Com base em 7 analistas de Wall Street que oferecem metas de preço de 12 meses para Verve Therapeutics Inc - Dist nos últimos 3 meses.
Informação Financeira
Custos administrativos e de venda
Custos Operacionais
Lucro antes de imposto
Vendas
Custo das vendas
Lucro bruto sobre vendas
Despesa com juros da dívida
EBITDA
Resultado Operacional
$
Sobre Verve Therapeutics Inc
Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
